The TriGUARD 3 Cerebral Embolic Protection Device is designed to minimize the risk of cerebral damage by deflecting embolic debris away from cerebral circulation during transcatheter aortic valve replacement (TAVR), but there is no evidence that it actually accomplishes that, according to the consensus of a U.S. Food and Drug Administration (FDA) advisory panel.